(RTTNews) – Grifols (GRFS) has agreed to acquire the remaining equity of Alkahest, Inc. in exchange for a total price of $146 million, on a debt-free basis. The closing of the deal is anticipated in early 2021.
In addition to the clinical development of specific plasma fractions and protein inhibitors, Alkahest is focused on developing a complete understanding of the human plasma proteome. Alkahest, as a wholly owned subsidiary within the Grifols innovation office, will focus on proteins with biological impact that change with age.
A Global Asset Management Seoul Korea Magazine